Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a note issued to investors on Monday, February 3rd. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($0.44) for the quarter, up from their prior estimate of ($0.96). Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio’s Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS and FY2028 earnings at ($4.77) EPS.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%.

Several other research firms have also recently commented on ANAB. Wells Fargo & Company cut their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Truist Financial lowered their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Trading Down 2.7 %

AnaptysBio stock opened at $16.06 on Wednesday. The stock has a 50 day moving average of $17.05 and a two-hundred day moving average of $26.77. AnaptysBio has a twelve month low of $12.51 and a twelve month high of $41.31. The stock has a market capitalization of $488.71 million and a price-to-earnings ratio of -2.64.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently added to or reduced their stakes in the business. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio in the third quarter valued at about $49,000. nVerses Capital LLC raised its position in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 644 shares in the last quarter. Point72 DIFC Ltd grew its holdings in AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 5,342 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,231 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.